Adrenomedullin, a hormone first identified in an adrenal medullary tumor, disrupts the effect of insulin on the endothelium of blood vessels, leading to insulin resistance linked to obesity and type 2 ...
Med-tech companies secured $2.76 billion across financings 56 transactions in January 2025, up from $1.72 billion in December ...
The immediate implementation of the U.S. NIH’s guidance to cut indirect costs included in its grants to 15% was quickly halted late Feb. 10 when a federal district judge granted a nationwide temporary ...
Researchers from the QIMR Berghofer Medical Research Institute in Queensland, Australia and Emory University have shown that a potential new targeted therapy for childhood brain cancer was effective ...
The U.K.’s National Institute for Health and Care Excellence (NICE) historically relies on cost savings to vet novel medical ...
The fast pace in which the Trump administration has rolled out changes to how government and businesses operate – a ...
Ellipses Pharma Ltd. has agreed to in-license global rights to GENA-104, a first-in-class immuno-oncology monoclonal antibody ...
For the pharmaceutical industry caught in the crosshairs of a potential trade war, the consequences of U.S. tariffs on China ...
Cognition Therapeutics Inc. evolved from the work of a neuroscientist and a chemist working in the San Francisco Bay area, seeking out targets to block the effects of Alzheimer’s disease. Since the ...
The closely watched chronic spontaneous urticaria (CSU, or hives) space chalked more early stage KIT inhibitor data as Third Harmonic Bio Inc. rolled out results from the phase I single and multiple ...
Newronika SpA's AlphaDBS recently secured an investigational device exemption from the U.S. FDA allowing it to begin a pivotal trial to evaluate the safety and efficacy of its adaptive deep brain ...
Researchers from the Centre for Addiction and Mental Health (CAMH) and affiliated organizations presented preclinical data for the α5-GABA-A receptor (α5-GABAAR) positive allosteric modulator GL-II-73 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results